12. The formulation of claim 9 which comprises enteric coated tablets or caplets, wax or polymer coated tablet or caplets or time-release matrices, or combinations thereof.

13. The formulation of claim 10 which comprises enteric coated tablets or caplets, wax or polymer coated tablet or caplets or time-release matrices, or combinations thereof.

14. The formulation of claim 9 which is a polymeric controlled release composition comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerized repeating unit and cross-linking agent, respectively with (2) water, in the presence of an SSRI.

15. The formulation of claim 10 which is a polymeric controlled release composition comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerized repeating unit and cross-linking agent, respectively with (2) water, in the presence of paroxetine, fluoxetine, fluroxamine or sertraline, or a pharmaceutically acceptable salt thereof.

16. The formulation of claim 15 in which the SSRI is paroxetine or a pharmaceutically acceptable salt thereof.

17. The formulation of claim 9, which is a system for the controlled release of an active substance which is an SSRI, comprising (a) a deposit-core comprising an effective amount of the active substance and having defined geometric form, and (b) a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable

polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric materials in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids.

18. The formulation of claim 10, which is a system for the controlled release of paroxetine, fluoxetine, fluroxamine or sertraline, or a pharmaceutically acceptable salt thereof, comprising (a) a deposit-core comprising an effective amount of the active substance and having defined geometric form, and (b) a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric materials in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids.

19. The formulation of claim 18 in which the SSRI is paroxetine or a pharmaceutically acceptable salt thereof.

20. A method of treating or preventing one or more of the disorders which comprises administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation of claim 9 to a sufferer in need thereof.

21. A method of treating or preventing one or more of the disorders which comprises administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation of claim 10 to a sufferer in need thereof.

22. A process for preparing a controlled or delayed release formulation of an SSRI which comprises combining (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80%